According to Zacks, “Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. “
Several other equities research analysts also recently weighed in on the company. HC Wainwright reissued a neutral rating and issued a $57.00 price target (up previously from $55.00) on shares of DENTSPLY SIRONA in a report on Tuesday, July 9th. ValuEngine cut Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd.
SLGL stock opened at $9.80 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.29 and a current ratio of 8.29. The stock has a fifty day simple moving average of $9.25. Sol Gel Technologies has a twelve month low of $5.41 and a twelve month high of $11.36. The stock has a market capitalization of $185.45 million, a price-to-earnings ratio of -5.44 and a beta of 0.49.
Sol Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings results on Wednesday, May 22nd. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.30. Sol Gel Technologies had a negative return on equity of 64.21% and a negative net margin of 686.02%. The firm had revenue of $6.36 million for the quarter, compared to analyst estimates of $0.89 million. As a group, equities research analysts forecast that Sol Gel Technologies will post -1.34 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Sol Gel Technologies stock. Clal Insurance Enterprises Holdings Ltd acquired a new stake in Sol Gel Technologies Ltd (NASDAQ:SLGL) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 59,987 shares of the company’s stock, valued at approximately $406,000. Clal Insurance Enterprises Holdings Ltd owned 0.32% of Sol Gel Technologies at the end of the most recent quarter. 20.40% of the stock is owned by institutional investors and hedge funds.
Sol Gel Technologies Company Profile
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
Further Reading: Earnings Per Share (EPS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.